All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|4|1127-1135

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.4, 2015-04, pp. : 1127-1135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the HALLMARK DUAL study

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 36, Iss. 10, 2016-10 ,pp. : 1433-1441

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 544-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 25-30

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C‐related cirrhosis, genotype 4

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 674-679

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

By  

HEPATOLOGY, Vol. 64, Iss. 4, 2016-10 ,pp. : 1049-1056

John Wiley & Sons Inc

Access to resources Recommend Favorite